Kelun Group
Kelun Group, officially known as Kelun Pharmaceutical Co., Ltd., is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in China (CN). Established in 2004, the company has rapidly expanded its operations across major regions, including Asia, Europe, and North America, solidifying its presence in the global market.
Specialising in the development and production of high-quality injectable drugs, Kelun Group is recognised for its innovative approach and commitment to research and development. The company’s core products include a diverse range of sterile injectables and oncology medications, distinguished by their advanced formulation techniques and stringent quality control measures.
With a strong market position, Kelun Group has achieved significant milestones, including numerous certifications and partnerships that enhance its reputation as a trusted provider in the pharmaceutical sector. Its dedication to excellence and patient safety continues to drive its success in the competitive landscape of pharmaceutical manufacturing.
-18 vs industry average
Kelun Group’s score of 20 is lower than 27% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Kelun Group?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Kelun Group's reported carbon emissions
Kelun Group, a pharmaceutical preparation manufacturer based in China, has reported its carbon emissions for recent years. In 2024, the company's total emissions were approximately 2.85 billion kg CO2e, comprising 2.36 billion kg CO2e from Scope 1 and 483.8 million kg CO2e from Scope 2. This represents a slight increase from 2023, when total emissions were about 2.66 billion kg CO2e, with Scope 1 emissions at approximately 2.19 billion kg CO2e and Scope 2 emissions at 468.9 million kg CO2e. In 2022, Kelun Group reported Scope 1 emissions of 12.62 million kg CO2e and Scope 3 emissions, specifically purchased goods and services, of 472.01 million kg CO2e. Scope 2 emissions were not disclosed for 2022. Kelun Group's emissions data is cascaded from its parent organisation, Sichuan Kelun Pharmaceutical Co., Ltd. The company has not yet disclosed specific reduction targets or commitments through initiatives like the Science Based Targets initiative (SBTi) or the Climate Pledge. Further disclosure on Scope 3 emissions and specific reduction strategies is awaited.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Kelun Group’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Kelun Group yet.
Scope 3 top emissions categories
1 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Emissions comparison with industry peers
View similar organisations
Kelun Group
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project